In a trial for treatments of Duchenne muscular dystrophy (DMD) injection of an AAV9 vector expressing mini-dystrophin resulted in TMA in 4 out of 15 male recipients between the ages of 7-12 years. Here, DMD is linked to Duchenne muscular dystrophy.